Impilo acquires Ferrosan Medical Devices, a global leading manufacturer of hemostats

PRESS RELEASE

Copenhagen 2017-07-07

Impilo has acquired 37 percent of the shares in Ferrosan Medical Devices (FeMD) that develops and produces hemostatic products used to stop bleeding during surgery, as well as miniature electrical engineering used in equipment for regional anesthesia and minimal invasive surgery. FeMD has approximately 220 employees and has production sites and offices in Søborg, Denmark, and in Szczecin, Poland. Sellers are a consortium of Nordic investors and the transaction closed at the end of June.

FeMD is a company with a strong product, development and manufacturing expertise. We have known them well since 2004 and see a company with strong competencies and growth potential. We look forward to supporting management in taking the next steps to develop the company,” says Hans-Christian Bødker Jensen, partner of Impilo and director of the Board of Directors of FeMD.

Impilo will be the largest shareholder in FeMD.

Ferrosan Medical Devices has a 70-year history. It has developed into a global, leading developer and manufacturer of gelatine-based hemostats, which helps surgeons control and stop bleeding during surgery. The products are distributed world-wide through a partnership with Ethicon (a Johnson&Johnson company).

Further, FeMD develops and produces miniature electrical engineering used in equipment for regional anesthesia and minimal invasive surgery. The annual turnover is approximately DKK 450 million and the company has extensive development and manufacturing activities at its plants in Copenhagen and Szczecin, Poland.

 “We welcome Impilo as the new main shareholder in FeMD. We have known Hans-Christian Bødker Jensen and Fredrik Strömholm since a long time and they also coordinated the investor consortium that acquired the company last year. We see great potential in both geographic expansion, especially in new growth regions, and continued innovation and broadening of use of our products,” says Henrik Krøis, CEO of FeMD.

FeMD’s Board of Directors consists of chairman Peter Kurstein, former CEO of Radiometer A/S which is a part of Danaher, Måns Barsne, Executive Vice President (Chief Innovation Officer) at Ambu A/S, Marianne Ovesen, head of Operations at Radiometer and Impilo-partners Fredrik Strömholm and Hans-Christian Bødker Jensen.

Impilo, which was established in 2017, has more than SEK 3 bn in capital from leading Nordic and international investors. 

_____________________________________________________________

For more information:

Hans-Christian Bødker Jensen, partner

hc.bodker@impilo.se

+45 22 70 20 10

Fredrik Strömholm, partner

fredrik.stromholm@impilo.se

+46 76-115 10 65

Impilo is an investment company focussed on investments in Nordic healthcare companies active in the pharmaceutical, medical devices, care services and other health related areas. Impilo’s perspective is that the portfolio companies must contribute to a positive development in their field and thus society in order to be successful longer term. 

Tags:

About Us

We are an investment company with an approach based on the premise that we must invest and drive development so as to produce a lasting, positive effect on the future of our investee companies, society at large and ourselves. A premise that also benefits our investment success, since it forces us to understand each business and reduce risks, and thereby develop our ability to act as progressive owners. We invest in people’s opportunities to enjoy healthier lives in the future.